RxDoctor Payments Data

Rahul Gaglani, MD

Cardiovascular Disease · Murrieta, CANPI 1558692657

Payments from drug & device makers

$10,161in general payments, 2019–2025

Across 356 payments — averaging $28.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Novartis$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$894
  • Abbott$589
  • Merck$523
  • Edwards Lifesciences$411
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$2,53225%
  • Food & beverage$7,57675%
  • Education$531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,161 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$344,172
Medicare patients
466
Services billed
2,177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$163,282
EntrestoSacubitril/Valsartan86$133,862
XareltoRivaroxaban27$40,936
BrilintaTicagrelor32$31,660
FarxigaDapagliflozin Propanediol25$25,108
Atorvastatin Calcium194$2,415
Metoprolol Succinate152$2,284
ClopidogrelClopidogrel Bisulfate159$2,053
Amlodipine Besylate137$1,029
Losartan Potassium100$996
Nifedipine ErNifedipine25$859
Carvedilol95$687
Rosuvastatin Calcium26$681
Isosorbide Mononitrate ErIsosorbide Mononitrate36$655
Valsartan19$582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$235$163,282120 claims
NovartisEntresto$1,029$133,86286 claims
AstraZenecaBrilinta, Farxiga$254$56,76857 claims
Johnson & JohnsonXarelto$220$40,93627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →